<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30457164</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>20</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1098-2744</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>20</Day>                    </PubDate>                </JournalIssue>                <Title>Molecular carcinogenesis</Title>                <ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>            </Journal>            <ArticleTitle>DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/mc.22941</ELocationID>            <Abstract>                <AbstractText>Breast cancer (BC) is a common malignancy worldwide. More than 3700 000 women die of BC every year. DSCAM-AS1 was overexpressed several kinds of cancer and miR-204-5p was lowly expressed, which indicated that miR-204-5p had anti-tumor activity and DSCAM-AS1 had pro-tumor activity. We intended to analyze DSCAM-AS1, miR-204-5p and ribonucleotide reductase M2 (RRM2). Microarray analysis and quantitative Real Time fluorescence Polymerase Chain Reaction (qRT-PCR) were employed to determine DSCAM-AS1 and miR-204-5p expression. Luciferase reporter assay was applied to examine the target relationship between DSCAM-AS1, miR-204-5p and RRM2. Cell Counting Kit-8 (CCK-8 assay), transwell assay and flow cytometry were used to detect cell proliferation, invasion and apoptosis. The expression of DSCAM-AS1, miR-204-5p and RRM2 were confirmed by Western blot. We also conducted in vivo assay to verify the effect of DSCAM-AS1. DSCAM-AS1 was up-regulated, while miR-204-5p was down-regulated in BC tissues and cells. DSCAM-AS1 directly targeted miR-204-5p. DSCAM-AS1 promoted the proliferation and invasion of BC cells by reducing miR-204-5p and inhibiting miR-204-5p expression. DSCAM-AS1 expression was related to the expression of RRM2, and miR-204-5p could reverse the function of DSCAM-AS1. RRM2 was up-regulated in BC cells, and miR-204-5p inhibited RRM2 expression by targeting RRM2. Overexpression of RRM2 stimulated proliferation and cell invasion and impeded apoptosis. In vivo experiments showed that knockdown of DSCAM-AS1 decreased the tumorigenesis of BC cells, increased the expression of miR-204-5p. DSCAM-AS1 promoted proliferation and impaired apoptosis of BC cells by reducing miR-204-5p and enhancing RRM2 expression. DSCAM-AS1/miR-204-5p/RRM2 may serve as novel therapeutic targets for BC. This article is protected by copyright. All rights reserved.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Liang</LastName>                    <ForeName>Wen-Hui</ForeName>                    <Initials>WH</Initials>                    <AffiliationInfo>                        <Affiliation>The Affiliated Center Hospital, Xinxiang Medical University, Xinxiang 453003, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang 453003, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Na</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Xinxiang Medical University, Xinxiang 453003, Henan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yuan</LastName>                    <ForeName>Zhi-Qing</ForeName>                    <Initials>ZQ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Xinxiang Medical University, Xinxiang 453003, Henan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Qian</LastName>                    <ForeName>Xin-Lai</ForeName>                    <Initials>XL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Xinxiang Medical University, Xinxiang 453003, Henan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Zhi-Hui</ForeName>                    <Initials>ZH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Xinxiang Medical University, Xinxiang 453003, Henan, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>20</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Mol Carcinog</MedlineTA>            <NlmUniqueID>8811105</NlmUniqueID>            <ISSNLinking>0899-1987</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">DSCAM-AS1</Keyword>            <Keyword MajorTopicYN="N">RRM2</Keyword>            <Keyword MajorTopicYN="N">miR-204-5p</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>11</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30457164</ArticleId>            <ArticleId IdType="doi">10.1002/mc.22941</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>